{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vinblastine+sulfate", "query": { "intervention": "Vinblastine sulfate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 117, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vinblastine+sulfate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T10:10:22.345Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03712202", "title": "Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage I Hodgkin Lymphoma", "Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma", "Ann Arbor Stage IA Hodgkin Lymphoma", "Ann Arbor Stage IB Hodgkin Lymphoma", "Ann Arbor Stage II Hodgkin Lymphoma", "Ann Arbor Stage IIA Hodgkin Lymphoma", "Ann Arbor Stage IIB Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lymphocyte-Rich Classic Hodgkin Lymphoma", "Ann Arbor Stage I Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Mixed Cellularity Classic HL", "Ann Arbor Stage II Nodular Sclerosis Classic HL" ], "interventions": [ { "name": "Bleomycin", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Vinblastine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 155, "start_date": "2018-11-28", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • San Diego, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712202" }, { "nct_id": "NCT01743157", "title": "Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Biochemo + bevacizumab then ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Pacific Medical Center Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2010-12", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2013-08-29", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01743157" }, { "nct_id": "NCT03646123", "title": "Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 255, "start_date": "2019-01-28", "completion_date": "2024-08-23", "has_results": true, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 55, "location_summary": "Fountain Valley, California • Aurora, Colorado • Colorado Springs, Colorado + 48 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646123" }, { "nct_id": "NCT01022996", "title": "Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Everolimus (RAD001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2009-12", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-05-18", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 16, "location_summary": "Los Angeles, California • Greenwood Village, Colorado • Orlando, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01022996" }, { "nct_id": "NCT03907488", "title": "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma", "Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lymphocyte-Rich Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Vinblastine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 994, "start_date": "2019-08-29", "completion_date": "2027-03-28", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 711, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907488" }, { "nct_id": "NCT00005090", "title": "S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2000-04", "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 47, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005090" }, { "nct_id": "NCT01534078", "title": "Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Adriamycin, vinblastine, and dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2012-03", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2018-02-20", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 4, "location_summary": "Tampa, Florida • Boston, Massachusetts", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534078" }, { "nct_id": "NCT00004010", "title": "Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "ABVD regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 99, "start_date": "1999-10", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2014-02-26", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 37, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 29 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004010" }, { "nct_id": "NCT00352027", "title": "Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Lymphoma" ], "interventions": [ { "name": "Adriamycin®", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Nitrogen Mustard", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Radiotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 81, "start_date": "2006-07-20", "completion_date": "2022-11-15", "has_results": true, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 6, "location_summary": "Palo Alto, California • San Diego, California • Portland, Maine + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Portland", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352027" }, { "nct_id": "NCT02205762", "title": "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Langerhans Cell Histiocytosis" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "INDOMETHACIN", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytosine Arabinoside", "type": "DRUG" }, { "name": "2-chlorodeoxyadenosine", "type": "DRUG" }, { "name": "hematopoietic stem cell transplantation (RIC-HSCT)", "type": "PROCEDURE" }, { "name": "Intravenous immunoglobulin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "North American Consortium for Histiocytosis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 1400, "start_date": "2016-11-02", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-23T10:10:22.345Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02205762" } ] }